Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts.

The aim of the present study was to assess the anti-tumor effect of a defective adenovirus that expresses soluble vascular endothelial growth factor (VEGF) receptor FLT-1 (AdsFLT-1) in combination with cisplatin (cis-diamminedichloroplatinum, DDP) on human tongue carcinoma Tca8113 cell xenografts that had been pre-established in nude mice. In vitro, Tca8113 cells secreted soluble FLT-1 (sFLT-1) after infection with AdsFLT-1, and the conditioned medium from AdsFLT-1-treated Tca8113 cells seemed to inhibit VEGF-induced proliferation of human umbilical vein endothelial cells. The combined effects of sFLT-1 gene therapy and DDP chemotherapy was then studied in well-established Tca8113 xenografts. The concentration of sFLT-1 in serum reached a peak 8 days after intratumoral injection of AdsFLT-1. In these tumors, AdsFLT-1 intratumoral injections had only a small effect. Interestingly, when the cells were also exposed to DDP chemotherapy, significantly higher (P<0.05), and possibly synergistic, anti-tumoral effects were observed that were highly correlated to a marked reduction in intratumoral vascularization and an increase in tumor-cell apoptosis. Together, these data emphasize the potential of combining an anti-angiogenic gene therapy strategy with a destructive approach directed against the tumor cells to fight human tongue carcinoma.

[1]  Barbara Mayer,et al.  Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  J. Schellens,et al.  Cisplatin resistance and DNA repair. , 1997, Cancer Treatment Reviews.

[3]  R. Crystal,et al.  Regional suppression of tumor growth by in vivo transfer of a cDNA encoding a secreted form of the extracellular domain of the flt-1 vascular endothelial growth factor receptor. , 1998, Human gene therapy.

[4]  K. Nakashiro,et al.  Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. , 2004, Oral oncology.

[5]  A. El-tarras,et al.  Clastogenic effects of cis-diamminedichloroplatinum. I. Induction of chromosomal aberrations in somatic and germinal cells of mice. , 1989, Mutation research.

[6]  M. Shibuya,et al.  Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. , 1990, Oncogene.

[7]  T. Veikkola,et al.  Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.

[8]  J. S. van de Gevel,et al.  Infection of human vascular endothelial cells with Staphylococcus aureus induces hyperadhesiveness for human monocytes and granulocytes. , 1997, Journal of immunology.

[9]  R. Kendall,et al.  Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. , 1996, Biochemical and biophysical research communications.

[10]  M. Taniwaki,et al.  cis-diamminedichloroplatinum(II)-induced sister-chromatid exchanges and chromosome aberration formation in cultured human lymphocytes and their inhibition by sodium thiosulfate. , 1990, Mutation research.

[11]  U. Kliesch,et al.  Micronucleus test in bone marrow of mice treated with 1-nitropropane, 2-nitropropane and cisplatin. , 1987, Mutation research.

[12]  Barnett Rosenberg,et al.  Charles F. Kettring prize. Fundamental studies with cisplatin , 1985 .

[13]  K.,et al.  Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Napoleone Ferrara,et al.  Clinical applications of angiogenic growth factors and their inhibitors , 1999, Nature Medicine.

[15]  S. Shah,et al.  In vitro and in vivo evidence suggesting a role for iron in cisplatin-induced nephrotoxicity. , 1998, Kidney international.

[16]  C. Bucana,et al.  Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-beta. , 1999, Cancer research.

[17]  A. Berner,et al.  Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma , 2004, Clinical & Experimental Metastasis.

[18]  H. Hamada,et al.  Gene Therapy for Pancreatic Cancer Using an Adenovirus Vector Encoding Soluble flt-1 Vascular Endothelial Growth Factor Receptor , 2002, Pancreas.

[19]  Y. Taketani,et al.  Soluble FLT-1 expression suppresses carcinomatous ascites in nude mice bearing ovarian cancer. , 2002, Cancer research.

[20]  R. D'Amato,et al.  Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Thomas.  Vascular Endothelial Growth Factor, a Potent and Selective Angiogenic Agent (*) , 1996, The Journal of Biological Chemistry.

[22]  A. Tates,et al.  Increased frequency of chromosomal damage in peripheral blood lymphocytes up to nine years following curative chemotherapy of patients with testicular carcinoma , 1991, Environmental and molecular mutagenesis.

[23]  T. Tanaka,et al.  Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. , 1994, Biochemical and biophysical research communications.

[24]  Asif Ahmed,et al.  Release and Complex Formation of Soluble VEGFR-1 from Endothelial Cells and Biological Fluids , 2000, Laboratory Investigation.

[25]  R. Kendall,et al.  Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[26]  D. Curiel,et al.  Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  E. Furth,et al.  Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Y. Kaneda,et al.  Soluble Flt-1 gene therapy for peritoneal metastases using HVJ-cationic liposomes , 2000, Gene Therapy.

[29]  W. Dewey,et al.  Cisplatin induced cell killing and chromosomal aberrations in CHO cells: treated during G1 or S phase. , 1993, Mutation research.

[30]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[31]  K. Inoue,et al.  Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. , 2000, Cancer research.